GlassScriptPhysician profile
Glenn Pomerance
NPI 1609868017
$3,365.08
in general payments reported to CMS, 2019-2025
19 companies · $384 in 2025
The $384 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $998 · 2020: $375 · 2021: $325 · 2022: $394 · 2023: $642 · 2024: $247 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,272.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $450.73 | 2022-2024 | Miebo, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $295.14 | 2019-2021 | |
| Allergan, INC. | $273.07 | 2019-2022 | |
| Abbvie INC. | $263.96 | 2022-2025 | |
| Alcon Vision LLC | $260.66 | 2019-2025 | Ngenuity, Rocklatan, Tryptyr |
| Oyster Point Pharma, INC. | $258.98 | 2022-2023 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $250.87 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $201.91 | 2019-2023 | |
| Lensar, INC. | $165.61 | 2025 | Lensar Laser System |
| Glaukos Corporation | $165.38 | 2020-2025 | Idosetr |
| Sun Pharmaceutical Industries INC. | $159.96 | 2019-2024 | Cequa |
| Johnson & Johnson Surgical Vision, INC. | $137.33 | 2019 | |
| Biotissue Holdings INC. | $131.67 | 2019-2024 | |
| Mallinckrodt Enterprises LLC | $121.83 | 2019 | |
| Ocular Therapeutix, INC. | $83.29 | 2020-2024 | Dextenza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lombart Brothers, INC. | $72.09 | 2021 | |
| Shire North American Group INC | $30.82 | 2019 | |
| Dompe US, INC. | $21.97 | 2024 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $19.81 | 2025 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Pomerance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.